Détails
Marque
Collection
n.c
Parution
2024-06-03
Pages
94 pages
EAN papier
9783031600609
Langue
Anglais
Informations ebook
EAN PDF
9783031600616
Prix
58,29 €
En savoir plus
Nb pages copiables 0
Nb pages imprimables 9
Taille du fichier 2970 Ko
EAN EPUB
9783031600616
Prix
58,29 €
En savoir plus
Nb pages copiables 0
Nb pages imprimables 9
Taille du fichier 14356 Ko
Compatibilité

mobile-and-tablet Pour vérifier la compatibilité avec vos appareils,
consultez la page d'aide

Auteur(s) du livre


Ana Catarina Silva is an Associate Professor of Pharmaceutical Technology and Pharmaceutical Biotechnology and Researcher at FP-I3ID, FP-BHS, Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal; and Senior Researcher at UCIBIO, Faculty of Pharmacy, University of Porto, Portugal. She has a European PhD in Pharmaceutical Sciences with specialization in Pharmaceutical Technology from the University of Porto; and a Graduation in Pharmaceutical Sciences from the University Fernando Pessoa, Porto, Portugal. Professor Silva is also the author of several works in the areas of Pharmaceutical Technology and Pharmaceutical Biotechnology (h-index of 25) with 55+ articles, 6 book chapters, 50+ posters, and 15 oral communications. She also edited 6 books in this field; and acted as invited editor of 12 special issues. Professor Silva was included in the World's Top 2% Scientists List, in 2021, 2022 and 2023, by Stanford University, USA, and served as a referee for 10+ international funding agencies and 50+ international scientific journals. She is also a member of the editorial board of the Springer book series: Advances in Biochemical Engineering/Biotechnology; and the journals Dermatological Drug Delivery from Frontiers in Drug Delivery; Chinese Chemical Letters; Current Drug Metabolism; and Biochemistry & Pharmacology: Open Access. She supervises of 6 PhD students (2 completed), 6 MSc students (5 completed), and 37 undergraduate students (34 completed). Her current research interests are focused on developing lipid-based nanosystems to improve drug delivery. In particular, nose-to-brain delivery and cutaneous delivery; the quality-by-design (QbD) approach to optimize formulations of lipid-based nanosystems; and the development of Biopharmaceuticals and Advanced Therapy Medicinal Products (ATMPs).

Avis clients

Suggestions personnalisées

Restez informé(e) des événements et promotions ebook

Paiements sécurisés

Paiements sécurisés